bioRxiv Science⌕ Search

Biology subjects

Pouwels, S. D.

Publications and source records attributed to Pouwels, S. D..

4 recordsLinked to original sources

Feasibility of adopting water displacement and 3D scanning methods to quantify lung volume reduction in ex vivo models

Lung volume reduction is a treatment for chronic obstructive pulmonary disease (COPD) patients with severe emphysema. Currently, in vivo animal models are used as a first step to quantify the efficiency of novel lung volume reduction treatments. By quantifying lung volume reduction in ex vivo samples, animal testing may be reduced. This study proposes two new methods for quantifying lung volume reduction in ex vivo tissue: water displacement and three-dimensional (3D) scanning. Porcine lung lobes were inflated and treated with cyanoacrylate glue to simulate lung volume reduction. Volume changes were measured using a custom water displacement setup and in a ventilated setting using a handheld Artec Space Spider 3D surface scanner. Both techniques detected post-treatment volume reductions. Water displacement offers a simple, cost-effective approach for isolated lung lobes, while 3D scanning enables volumetric analysis of intact lungs under ventilated conditions. These methods provide a reliable intermediate step between in vitro and in vivo testing, reducing animal use and improving preclinical assessment of novel lung volume altering interventions.

bioengineering↗

Differential collagen crosslinking and network organization creates distinct tissue remodeling patterns in fibrosis and COPD

Collagens are key components of the extracellular matrix (ECM) that play a crucial role in maintaining structure, strength, and function of the lungs. Fibrillar collagens are crosslinked by enzymes such as lysyl oxidases and transglutaminases and organized into networks by proteoglycans and glycoproteins. Collagens are the main load-bearing components and along with elastin may impart a non-linear strain hardening behavior to the lung. In disease, collagen crosslinking and organization can be disrupted, possibly due to abnormal levels of enzymes or ECM components. Few studies have examined collagen crosslinking and organization in healthy and diseased human lungs. In this study, alterations in collagen crosslinking and organization were investigated in human lung control, fibrotic and chronic obstructive pulmonary disease (COPD) tissue sections. Ultra-performance liquid chromatography and second harmonic generation microscopy measured pyridinoline crosslinks and the distribution of mature and immature collagens within the decellularized scaffolds, respectively. Fibrotic scaffolds had higher total collagen but less crosslinking per mole of collagen compared with COPD donors. Image analysis by second harmonic generation microscopy showed mature collagens populated airway or blood vessel walls in all three groups and in the parenchyma of fibrotic scaffolds. Immature collagens, on the other hand, were mainly localized to parenchymal regions in control and COPD scaffolds, with fewer immature collagens in fibrotic parenchyma. Additionally, quantification of the mature to immature collagen ratio in defined regions of control and diseased scaffolds showed increased organized collagen in fibrotic tissue. Our study shows that collagen crosslinking and organization are disrupted in fibrotic and COPD lungs and these changes may be compartment specific and can contribute to aberrant mechanical properties of diseased lungs. Our findings highlight that along with total collagen content, collagen crosslinking and organization are equally important while investigating collagen-mediated pathological changes in lung tissue. These changes may have implications for developing ECM-based therapeutics for patients with lung diseases.

molecular biology↗

The lung extracellular matrix protein landscape in severe early-onset and moderate chronic obstructive pulmonary disease.

Extracellular matrix (ECM) remodeling has been implicated in the irreversible obstruction of airways and destruction of alveolar tissue in chronic obstructive pulmonary disease (COPD). Studies investigating differences in the lung ECM in COPD have mainly focused on some collagens and elastin, leaving an array of ECM components unexplored. We investigated the differences in the ECM landscape comparing severe-early onset (SEO-) COPD and moderate COPD to control lung tissue for collagen type I chain 1 (COL1A1), COL6A1, COL6A2, COL14A1, fibulin 2 and 5 (FBLN2, FBLN5), latent transforming growth factor-beta binding protein 4 (LTBP4), lumican (LUM), versican (VCAN), decorin (DCN), and elastin (ELN) using image analysis and statistical modelling. Percentage area and/or mean intensity of expression of LUM in the parenchyma, and COL1A1, FBLN2, LTBP4, DCN, and VCAN in the airway walls, was proportionally lower in COPD compared to controls. Lowered levels of most ECM proteins were associated with decreasing FEV1 measurements, indicating a relationship with disease severity. Furthermore, we identified six unique ECM signatures where LUM and COL6A1 in parenchyma and COL1A1, FBLN5, DCN, and VCAN in airway walls appear essential in reflecting the presence and severity of COPD. These signatures emphasize the need to examine groups of proteins to represent an overall difference in the ECM landscape in COPD, that are more likely to be related to functional effects, than individual proteins. Our study revealed differences in the lung ECM landscape between control and COPD and between SEO and moderate COPD signifying distinct pathological processes in the different subgroups. NEW & NOTEWORTHYOur study identified COPD-associated differences in the lung ECM composition. We highlight the compartmental differences in the ECM landscape in different subtypes of COPD. The most prominent differences were observed for severe-early onset COPD. Moreover, we identified unique ECM signatures that describe airway walls and parenchyma providing insight into the intertwined nature and complexity of ECM changes in COPD that together drive ECM remodeling and may contribute to disease pathogenesis.

molecular biology↗

Substrate stiffness engineered to replicate disease conditions influence senescence and fibrotic responses in primary lung fibroblasts

In idiopathic pulmonary fibrosis (IPF) there is excessive ECM deposition, increased stiffness and ultimately destruction of lung parenchyma. IPF presents mainly in the elderly, implying that senescence, a hallmark of ageing, contributes to disease progression. Several studies have reported that IPF is characterised by increased senescence and accumulating evidence suggests that structural changes, such as increased stiffness may contribute to senescence. This study therefore investigated if increased tissue stiffness could modulate markers of senescence and/or fibrosis in primary lung fibroblasts. Using hydrogels representing healthy and fibrotic stiffnesses, we cultured primary fibroblasts from non-diseased lung tissue on top of these hydrogels for up to seven days before assessing senescence and fibrosis markers. Fibroblasts cultured on stiff ({+/-}15kPa) hydrogels showed higher Yes-associated protein-1 (YAP) nuclear translocation compared to soft hydrogels. When looking at senescence-associated proteins we also found higher secretion of receptor activator of nuclear factor kappa-B ligand (RANKL) but no change in transforming growth factor-{beta}1 (TGF-{beta}1) or connective tissue growth factor (CTGF) expression and higher decorin protein deposition on stiff matrices. With respect to genes associated with fibrosis, fibroblasts on stiff hydrogels compared to soft had higher expression of smooth muscle alpha ()-2 actin (ACTA2), collagen (COL) 1A1 and fibulin-1 (Fbln1) and higher Fbln1 protein deposition after seven days. Our results show that exposure of lung fibroblasts to fibrotic stiffness activates genes and secreted factors that are part of fibrotic responses and part of the senescence-associated secretory profile (SASP). This overlap may contribute to the creation of a feedback loop whereby fibroblasts create a perpetuating cycle reinforcing disease progression in IPF.

cell biology↗